Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (11-20 of 194) with videos related to

Pageof 20
Sort By:
Pharmacoeconomics|September 4, 1996
Economics of serotonin 5-HT3 antagonistsJ Bonneterre, C Bercez
Pathologie-Biologie|February 1, 1989
[Nausea and vomiting induced by anticancer chemotherapy: mechanisms and prevention]J Bonneterre, L Adenis
La Revue De Medecine Interne|June 28, 2003
[Gene therapy of melanoma: review of published clinical trials]N Penel, J Bonneterre
Lille Medical : Journal De La Faculte De Medecine Et De Pharmacie De L'Universite De Lille|October 1, 1979
[HL-A and cancer]J Bonneterre, P Cappelaere
Bulletin Du Cancer|March 16, 2001
[Aromatase inhibitors]L Mauriac, J Bonneterre
Bulletin Du Cancer|December 1, 1995
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over studyJ Bonneterre, B Hecquet
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?A Adenis, J Bonneterre
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1991
Chemotherapy in advanced gastric carcinomaA Adenis, J Bonneterre
Cancer Treatment Reviews|April 1, 1993
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study GroupJ Bonneterre, M Mercier
LARC Medical|June 1, 1983
[Genetics and cancers]A Demaille, J Bonneterre
Pageof 20

Showing results (11-20 of 194) with videos related to

Sort By:
Pageof 20
Pharmacoeconomics|September 4, 1996
Economics of serotonin 5-HT3 antagonistsJ Bonneterre, C Bercez
Pathologie-Biologie|February 1, 1989
[Nausea and vomiting induced by anticancer chemotherapy: mechanisms and prevention]J Bonneterre, L Adenis
La Revue De Medecine Interne|June 28, 2003
[Gene therapy of melanoma: review of published clinical trials]N Penel, J Bonneterre
Lille Medical : Journal De La Faculte De Medecine Et De Pharmacie De L'Universite De Lille|October 1, 1979
[HL-A and cancer]J Bonneterre, P Cappelaere
Bulletin Du Cancer|March 16, 2001
[Aromatase inhibitors]L Mauriac, J Bonneterre
Bulletin Du Cancer|December 1, 1995
Granisetron (IV) compared with ondansetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over studyJ Bonneterre, B Hecquet
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?A Adenis, J Bonneterre
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1991
Chemotherapy in advanced gastric carcinomaA Adenis, J Bonneterre
Cancer Treatment Reviews|April 1, 1993
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study GroupJ Bonneterre, M Mercier
LARC Medical|June 1, 1983
[Genetics and cancers]A Demaille, J Bonneterre
Pageof 20